Omeprazole (marketed as Prilosec and generic products), Esomeprazole (marketed as Nexium)
December 11, 2007
Audience: Gastroenterologists, other healthcare professionals, consumers
[UPDATE 12/11/2007] FDA informed healthcare professionals of the issuance of the Agency's follow-up communication regarding its review of safety data for the drugs omeprazole and esomeprazole that raised concerns about a potential increased risk of heart problems for patients treated with these drugs. The Agency conducted a comprehensive review of the data from two studies that were submitted to FDA. FDA continues to believe that long-term use of omeprazole or esomeprazole is not likely to be associated with an increased risk of heart problems and recommends that healthcare providers continue to prescribe and patients continue to use these products in the manner described in the labeling for the two products. See the "Update of Safety Review" for information regarding the two studies that were reviewed.
Sa Drugs.com - najnovije saopstenje o Omeprazolu. Jos jednom potvrdjena neosnovanost straha koji se cesto siri kod pacijenata od strane pojedinih lekara i farmaceuta. Lek ZA SADA
nema dokazane nikakve kancerogene efekte, niti je dokazano da izaziva srcane tegobe.